Evidence mapPaperPMID 39639719Full record

ArticleAIDS (London, England)2025

Cytokine trajectory over time in men and women with HIV on long-term antiretroviral therapy.

Christophe Vanpouille, Alan Wells, Victor DeGruttola, Miranda Lynch, Xinlian Zhang, Wendy Fitzgerald, Xin Tu, Antoine Chaillon, Alan Landay, Kathleen Weber and 3 more

Abstract read
In one paragraph

Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christophe VanpouilleEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Alan WellsDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Victor DeGruttolaDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Miranda LynchDepartment of Biostatistics and Bioinformatics, Hauptman-Woodward Medical Research Institute, Buffalo, NY, USA.
Xinlian ZhangDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Wendy FitzgeraldEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Xin TuDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Antoine ChaillonDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Alan LandayDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
Kathleen WeberHektoen Institute of Medicine/Cook County Health, Chicago, IL, USA.
Eileen ScullyDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Jonathan KarnDepartment of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Sara GianellaDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
Sex-differences in HIV persistence and Immune Dynamics during Reproductive AgingR01AI181655 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, JONATHAN KARN · 2023 to 2026
$3.2M
The HIV-associated Opioid Micro-Environment (HOME) ProjectDP2DA051915 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GIANELLA WEIBEL, SARA · 2020 to 2020
$2.4M
Intramural NIH HHS Z99 HD999999NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI181655NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI164559NIDA NIH HHS DP2 DA051915
6 · The paper itself

Abstract

objectiveAlthough antiretroviral therapy (ART) suppresses viral replication and reduces inflammation, it does not lead to the normalization of cytokines. The long-term effects of ART beyond viral suppression have not been studied and are mostly limited to cross-sectional research.

designThe impact of long-term ART on the trajectory of 40 cytokines/chemokines in 31 men and 59 women who maintained viral suppression over a median period of 6 years (317 visits ranging from 24 to 384 weeks post ART initiation) were measured by Luminex.

methodsWe used a generalized additive model with a Gaussian distribution and identity link function to model concentrations over time and investigate sex and race differences.

resultsWhile most cytokine/chemokine trajectories remained stable, the trajectory of nine markers of monocyte/macrophage activation (IP-10, I-TAC, MIG, sCD163, sCD14, MCP-1, MIP-3β, CXCL13, TNF-α) decreased over time (adj. P < 0.05). Despite continuous viral suppression, M-CSF, IL-15, and LBP increased over time (adj. P < 0.05). sCD14 was the only cytokine whose trajectory differed by sex (adj. P = 0.033). Overall, women had lower mean levels of IL-18 but higher levels of sCD14 than did men (adj. P < 0.05). GROα, LBP, and sCD14 showed significant differences between races (adj. P < 0.05). No association between cytokines and cellular HIV DNA/RNA was found.

conclusionOur study reveals a continuous decline in markers of monocyte/macrophage activation over 6 years of suppressive ART, indicating that long-term treatment may mitigate inflammaging and cardiovascular-related outcomes. The higher levels of sCD14 observed in women are consistent with them having greater innate immune activation than men do.

Indexed as

CytokinesHIV InfectionsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCross-Sectional StudiesFemaleHumansMaleMiddle AgedSex FactorsSustained Virologic ResponseAnti-Retroviral AgentsCytokines

Identifiers

PMID39639719
PMCPMC11631044

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.